IEX vs ROP: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ROP is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IEX and ROP share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IEX and ROP exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

IDEX Corporation is an applied solutions company that designs and manufactures highly engineered pumps, flow meters, valves, fluidic systems, and other components used to move and measure fluids. It operates across three reporting segments: Health & Science Technologies (precision fluidics, optics, and sealing for life science, analytical instruments, and semiconductors), Fluid & Metering Technologies (industrial pumps, metering, and water and wastewater equipment), and Fire & Safety/Diversified Products (rescue tools, fire suppression components, and dispensing equipment). Its products are typically small pieces of larger customer systems where reliability matters more than price, which supports pricing power and recurring aftermarket demand.

Full IEX guide

Roper Technologies has spent the past decade reinventing itself from an industrial tools and equipment maker into a diversified holding company whose center of gravity is vertical-market software. It operates through three segments: Application Software (businesses like Deltek for government contractors, Vertafore in insurance, Aderant for law firms, Frontline in K-12 education, and Clinisys in diagnostics), Network Software (network-effect platforms such as DAT in freight and iPipeline in insurance), and Technology Enabled Products (Neptune water meters, Verathon and CIVCO in medical devices). More than half of total revenue is now recurring, coming from SaaS subscriptions, maintenance and transaction fees, and application plus network software together generate roughly three-quarters of revenue.

Full ROP guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• IEX drivers: Health & Science Technologies momentum; Disciplined bolt-on acquisitions.
• ROP drivers: Acquisition-driven compounding; Recurring, high-margin software mix.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: IDEX is exposed to broad industrial cyclicality, and softness in chemical and certain short-cycle end markets has periodically offset strength elsewhere. For ROP, the clearest risk is valuation: ROP trades at a premium multiple, so disappointing results or a slower deal pace can compress the stock even if the business stays healthy.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick IEX if you believe its drivers more; ROP if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the IEX and ROP guides.

IEX. As of July 2026 IEX traded around $224 with a market cap near $16.5 billion and a trailing P/E in the low 30s, a premium typical of high-quality, acquisitive industrials. The valuation reflects consistent margins, record orders, and raised guidance, but it also leaves limited cushion if end markets weaken. The dividend yield sits near 1.3%, with the company having raised its payout for more than 15 consecutive years.

ROP. Roper's Q1 2026 revenue rose about 11% year over year to roughly $2.10 billion, split between 6% organic growth and 5% from acquisitions, and it raised full-year adjusted earnings guidance while adding to its buyback authorization. Net margins sit near 19% to 20% and adjusted EBITDA margins around 38%, reflecting the software-heavy mix. The forward multiple in the mid-to-high teens is well below the stock's longer-run median, which bulls read as more reasonable and bears view as still-full for a business dependent on ongoing M&A.

Headline figures (approximate, July 2026): IEX shows revenue (ttm) ~$3.4B, q1 2026 net sales ~$887M (+9% YoY), q1 2026 orders ~$988M (record, +13%), adjusted ebitda margin ~26%; ROP shows revenue (ttm) ~$8.0 billion, q1 2026 revenue ~$2.10 billion (up ~11% YoY), market cap ~$35-36 billion, fy2026 adjusted deps guidance ~$21.80-$22.05.

IEX and ROP are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined IEX and ROP exposure against your real portfolio. It is not an investment adviser.